The second half includes 17 chapters, each covering a disease entity or a specific clinical problem (eg, bone metastases). Most chapters are well written and adequately describe staging, treatment, and prognosis, as well as the role, strengths, and weaknesses of PET and CT, respectively, in the clinical setting. But with a few exceptions (eg, the chapter on pediatric malignancies), the chapters are not current. A comprehensive textbook cannot be up to date in the same manner that individual research articles can, but the field of PET-CT is rapidly developing and a certain degree of topicality must be sought. For example, the majority of the references in the chapter on lymphoma are from before 2001, and the latest is from 2004. A similar tendency is found in the chapters on lung, head and neck, and colorectal cancer, with the most recent reference from 2006. An example of the lack of topicality is found in the chapter on testicular malignancies (p 363): “The results of the recent trial from the UK (TE22) on this subject (staging by PET-CT) are still pending.” The TE22 study examined if fluorodeoxyglucose PET could identify patients without occult metastatic disease and was stopped prematurely because of a high relapse rate in patients with negative PET findings. Preliminary results were published in 2007.